|Mr. Robert W. Weber||CFO, Chief Accounting Officer, VP of Operations, Controller and Sec.||242.6k||N/A||66|
|Dr. Christopher L. Reading Ph.D.||Chief Scientific Officer||188.81k||N/A||69|
|Mr. Scott A. Rieger||VP of Corp. Communications||N/A||N/A||N/A|
|Mr. Robert L. Marsella||Sr. VP of Bus. Devel. and Marketing||N/A||N/A||64|
Harbor Diversified, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of products for the treatment of diseases related to aging. The company primarily focuses on the development of a series of steroid hormone analogs that are derived from the human adrenal metabolome. Its development-stage product candidates that have completed Phase I/IIa clinical trials include Apoptone (HE3235) for use in patients with late-stage prostate cancer; and Triolex (HE3286) used in obese type 2 diabetes mellitus patients. The company was formerly known as Harbor BioSciences, Inc. and changed its name to Harbor Diversified, Inc. in February 2012. Harbor Diversified, Inc. was founded in 1992 and is headquartered in San Diego, California.
Harbor Diversified, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.